["N2" carcinoma of the lung. Therapeutic considerations].
The follow-up of 240 N2 lung cancer cases operated in Thoracic and Cardiovascular Surgery Department of Florence is examined. The analysis is performed in compliance with global survival, "T", histology, therapeutic choices. Global survival is 81% after 6 months, 60% after 1 year, 37% after 2 years, 26% after 3 years, 23% after 4 years, 23% after 5 years. Significative difference on survival does not exist between principal histologic types (squamous, adenocarcinoma, adenosquamous). Raising the "T" survival decreases, but only for adenocarcinoma. Different therapeutic options (only surgery, surgery+radiotherapy, surgery+chemotherapy, surgery+radio and chemotherapy) do not influence the survival in a way statistically significative. From the literature, any certainty about radiotherapy and chemotherapy associated to surgery for N2 lung cancer treatment does not exist at the moment. Thus radical surgery is essential.
Ugolini
D
D
UO di Chirurgia Toracica, Azienda Ospedaliera di Careggi--Firenze.
Boddi
V
V
Notaristefano
T
T
Santini
P
P
Regio
S
S
Gigli
P
P
Dragotto
A
A
Laino
G M
GM
Salani
G
G
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008168:Lung / Q000601:surgery; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D015996:Survival Rate
Carcinoma del polmone "N2". Considerazioni terapeutiche.